<?xml version="1.0" encoding="UTF-8"?>
<p id="p0245">Ben-jebria et al. formulated pulmonary aerosol drug delivery for porous microparticles. It was found that particles deposit inside the lower lungs was increased as compared to conventional dosage form. The systemic bioavailability by pulmonary route was increased using porous microparticles [
 <xref rid="bb0350" ref-type="bibr">70</xref>]. It was also observed that drug release from the formulation was sustained, which is required in COVID-19 patients.
</p>
